Clinical Trial Update: Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib [Phase 2]

View source ↗

Summary

Phase 2 trial update on using glutamine to prevent peripheral neuropathy in patients with multiple myeloma treated with bortezomib; study status terminated with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Peripheral Neuropathy

Drugs mentioned

• Bortezomib (bortezomib)
• Glutamine (glutamine)

Snippet

Sponsor: Beth Faiman | Conditions: Chemotherapeutic Agent Toxicity, Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2019-10-22